1. 1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score. (September 2015) Authors: Stemmer, S.; Steiner, M.; Rizel, S.; Ben-Baruch, N.; Soussan-Gutman, L.; Rosengarten, O.; Geffen, D.; Nisenbaum, B.; Ryvo, L.; Uziely, B.; Fried, G.; Svedman, C.; Rothney, M.; Klang, S.; Kaufman, B.; Isaacs, K.; Evron, E.; Zidan, J.; Shak, S.; Liebermann, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study. (March 2017) Authors: Stemmer, S.; Steiner, M.; Rizel, S.; Geffen, D.; Nisenbaum, B.; Peretz, T.; Isaacs, K.; Rosengarten, O.; Fried, G.; Svedman, C.; Ben-Baruch, N. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗